Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas

Neoplastic cells are a rare component in human glioblastoma microvasculature

(2015) Fausto J. Rodriguez et al.   Oncotarget

IDH1Mutations in Oligodendroglial Tumors: Comparative Analysis of Direct Sequencing, Pyrosequencing, Immunohistochemistry, Nested PCR and PNA-Mediated Clamping PCR

(2012) Dakeun Lee et al.   BRAIN PATHOLOGY

IDH mutations in acute myeloid leukemia

(2012) Dinesh Rakheja et al.   HUMAN PATHOLOGY

Prognostic Impact of CD133 mRNA Expression in 48 Glioblastoma Patients Treated with Concomitant Radiochemotherapy: A Prospective Patient Cohort at a Single Institution

(2011) Philippe Metellus et al.   ANNALS OF SURGICAL ONCOLOGY

Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing

(2011) Shingo Takano et al.   Brain Tumor Pathology

Inconsistent Immunohistochemical Expression Patterns of Four Different CD133 Antibody Clones in Glioblastoma

(2011) Simon K. Hermansen et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients

(2011) Philippe Metellus et al.   JOURNAL OF NEURO-ONCOLOGY

Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer

(2011) Hee Joung Kim et al.   LUNG CANCER

Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas

(2010) Juan L Garcia et al.   BMC CANCER

Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis

(2010) Roberto Pallini et al.   CANCER

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

Detection of Low-Level KRAS Mutations Using PNA-Mediated Asymmetric PCR Clamping and Melting Curve Analysis with Unlabeled Probes

(2010) Ji Eun Oh et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Biology of glioma cancer stem cells

(2009) Deric M. Park et al.   MOLECULES AND CELLS

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD133 as a Marker for Cancer Stem Cells: Progresses and Concerns

(2009) Yaojiong Wu et al.   STEM CELLS AND DEVELOPMENT

Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme

(2008) R. Pallini et al.   CLINICAL CANCER RESEARCH

Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients

(2008) F. Zeppernick et al.   CLINICAL CANCER RESEARCH

Presence of pluripotent CD133+ cells correlates with malignancy of gliomas

(2008) Niklas Thon et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

High-grade glioma before and after treatment with radiation and Avastin: Initial observations

(2008) Ingeborg Fischer et al.   NEURO-ONCOLOGY